LiveNSE delayed · 128/128 · 20 Aug 2026, 10:45 am
Scores stay the 15 Aug 2026 desk snapshot. Not advice.

Highest-conviction sleeve

If I could own only 5

An analytical ranking of the five names the desk would keep if forced to concentrate. This is not financial advice, not a recommended portfolio, and not a prediction. Position sizing, tax and suitability are yours.

Conviction 1 · KAYNES

Kaynes Technology India Ltd

68.2/100
10X Medium
Moderate Risk
Last price
₹3,870.9+1.24%
Market cap
₹20,283 Cr
Base case
2.8x · ₹79,818 Cr
Bull case
6.4x · ₹1.82 Lakh Cr
Major risk
Repeated equity issuance

High-complexity EMS plus OSAT optionality on India's manufacturing relocation.

Why it could outperform — durable, accelerating growth rather than a one-off spike; a 10x revenue runway from India + export themes.

Conviction 2 · APAR

Apar Industries Ltd

68.8/100
10X Low
Moderate Risk
Last price
₹16,773.0+0.95%
Market cap
₹66,750 Cr
Base case
2.2x · ₹69,838 Cr
Bull case
4.8x · ₹1.50 Lakh Cr
Major risk
T&D capex is still a cycle

Power-grid pick-and-shovel with three engines and still-reasonable economics.

Why it could outperform — a 3x revenue runway from India + export themes.

Conviction 3 · DATAPATTNS

Data Patterns (India) Ltd

74.8/100
10X Low
Moderate Risk
Last price
₹4,822.6+1.01%
Market cap
₹27,036 Cr
Base case
2.4x · ₹35,618 Cr
Bull case
5.3x · ₹78,937 Cr
Major risk
Order and revenue lumpiness

Indigenous defence-electronics IP with a long order runway and scarce listed peers.

Why it could outperform — durable, accelerating growth rather than a one-off spike; a 10x revenue runway from India + export themes.

Conviction 4 · FINEORG

Fine Organic Industries Ltd

62.9/100
10X Low
Moderate Risk
Last price
₹5,254.9+2.43%
Market cap
₹16,216 Cr
Base case
1.9x · ₹30,484 Cr
Bull case
4.1x · ₹64,791 Cr
Major risk
Growth has decelerated to low-double digits

High-ROCE additives franchise that can keep compounding without leverage or theatre.

Why it could outperform — high-teens+ returns on capital while still reinvesting; a 3x revenue runway from India + export themes.

Conviction 5 · RAINBOW

Rainbow Children's Medicare Ltd

68.2/100
10X Low
Moderate Risk
Last price
₹1,462.0+0.01%
Market cap
₹14,850 Cr
Base case
2.2x · ₹31,892 Cr
Bull case
4.3x · ₹61,766 Cr
Major risk
New-city execution is unproven at scale

Paediatric hospital compounder with a long new-hospital runway and scarce listed peers.

Why it could outperform — a 5x revenue runway from India + export themes.